Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

Simple item page
dc.contributor.authorHicks, J. Kevin
dc.contributor.authorBishop, Jeffrey R.
dc.contributor.authorSangkuhl, Katrin
dc.contributor.authorMüller, Daniel J
dc.contributor.authorJi, Yuan
dc.contributor.authorLeckband, Susan G.
dc.contributor.authorLeeder, J. Steven
dc.contributor.authorGraham, Rebecca L.
dc.contributor.authorChiulli, Dana L.
dc.contributor.authorLLerena, Adrián
dc.contributor.authorSkaar, Todd C.
dc.contributor.authorScott, Stuart A.
dc.contributor.authorStingl, Julia C.
dc.contributor.authorKlein, Teri E.
dc.contributor.authorCaudle, Kelly E.
dc.contributor.authorGaedigk, Andrea
dc.contributor.departmentDepartment of Medicine, IU School of Medicineen_US
dc.date.accessioned2015-11-16T20:19:10Z
dc.date.available2015-11-16T20:19:10Z
dc.date.issued2015-08
dc.description.abstractSelective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationHicks, J. K., Bishop, J. R., Sangkuhl, K., Müller, D. J., Ji, Y., Leckband, S. G., … Gaedigk, A. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clinical Pharmacology and Therapeutics, 98(2), 127–134. http://doi.org/10.1002/cpt.147en_US
dc.identifier.urihttps://hdl.handle.net/1805/7452
dc.language.isoen_USen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1002/cpt.147en_US
dc.relation.journalClinical Pharmacology and Therapeuticsen_US
dc.rightsIUPUI Open Access Policyen_US
dc.sourcePMCen_US
dc.subjectSSRIsen_US
dc.subjectParoxetineen_US
dc.subjectFluoxetineen_US
dc.subjectFluvoxamineen_US
dc.subjectCitalopramen_US
dc.subjectEscitalopramen_US
dc.subjectSertralineen_US
dc.subjectPharmacogenomicsen_US
dc.subjectPersonalized medicineen_US
dc.subjectCPICen_US
dc.titleClinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitorsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
nihms689584.pdf
Size:
122.5 KB
Format:
Adobe Portable Document Format
Description:
Main Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.88 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles
Department of Medicine Works
Todd Skaar